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1. Introduction
  Malaria is an infectious disease that continues to be a 
major health problem in tropical and subtropical countries. 
According to WHO report, about 3.3 billion people - half 
of the world’s population - are at risk of malaria. This 
leads to about 250 million malaria cases occurring annually 
and estimates of one million deaths per year[1]. Among 
all species of malaria that are able to infect humans, 
Plasmodium falciparum (P. falciparum) causes most of 
severe malaria and deaths worldwide[1]. In some areas, 
mortality rates among malaria patients remain high, for a 
number of reasons, including limited access to healthcare 
services and increased drug resistance. The clinical 
manifestations of P. falciparum malaria patients are highly 
diverse and complex. Clinical outcome may range from a 
mild headache and fever, to a life-threatening condition; 
this variability results from a complex interplay among 
parasite, host, and environmental factors[2]. Improved 
classification of severe malaria could help clinicians who 
care for malaria patients avoid diagnostic delays, identify 
severe malaria patients who are most likely to die, and thus 
improve management, by targeting resources to the sickest 
patients. 
  In previous reports, several factors of life-threatening 
malaria were investigated[2-5]. However, mostly, the 
indicators of life-threatening malaria were studied in 
endemic areas and included children, in Africa. Few studies 
have reported on areas of unstable malaria transmission, 
in Southeast Asia. Here, we report the results of a malaria 
study in the Hospital for Tropical Diseases, a tertiary-care 
setting, in Thailand. The main objective of this study was 
to investigate indicators associated with lethal outcomes 
among adult patients with severe P. falciparum malaria, 
using WHO criteria, 2000[6].
Objective: To illustrate the clinical features and investigate the indicators associated with a fatal 
outcome in adult patients with severe Plasmodium falciparum malaria admitted to the Hospital 
for Tropical Diseases, Bangkok, Thailand. Methods: We studied 202 adult malaria patients 
admitted to the Intensive Care Unit. A total of 43 clinical variables were identified by univariate 
and logistic regression analyses, to eliminate confounding factors. Results: Regarding the 
statistical methods, only 6 variables-jaundice, cerebral malaria, metabolic acidosis, body mass 
index, initial respiratory rate, and white blood cell count-were significant indicators of death, 
with adjusted odds ratios (95% CI) of 15.2 (2.1-32.3), 4.3 (2.3-12.6), 3.3 (2.3-5.7), 2.4 (1.9-3.5), 2.2 
(1.5-2.6), and 1.7 (1.2-3.1), respectively. Conclusions: Our study found that jaundice, cerebral 
malaria, metabolic acidosis, body mass index, initial respiratory rate and white blood cell count 
were indicators of fatal outcome in severe Plasmodium falciparum malaria. Further studies on 
the fatal indicators in severe malaria need to be compared with data from different geographical 
areas, to construct practical measures to address potentially fatal indicators in different settings.
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2. Materials and methods
2.1. Study site and recruitment procedures
  The study was conducted at the Hospital for Tropical 
Diseases (HTD), a tertiary-care hospital for the management 
of tropical diseases, particularly severe malaria, located 
in Bangkok, Thailand. The hospital was well-equipped 
to provide intensive care for cases of severe malaria. The 
study protocol was reviewed and approved by the Ethics 
Committee of the Faculty of Tropical Medicine, Mahidol 
University, Thailand. Due to the limited number of death 
cases by severe malaria occurred in the study site, we made 
the enrollment ratio of fatal case per survival case to 1:5. 
An independent statistician generated a randomized list of 
surviving patients, before recruitment into the study. A total 
of 202 in-patients had positive asexual P. falciparum blood 
films, confirmed by microscopy, and classified as severe 
malaria according to the WHO criteria, 2000[6]. Of the 202 
patients, 157 (77.8%) were male and 45 (22.2%) female, with 
an average age (依SD) of (29.16 依12.10) years[range (15-74) 
years]. No significant concomitant disease was found in any 
of the patients. Among these, 170 were cured and discharged 
well on day 28 post-treatment; there were 32 deaths. All 
patients who fulfilled the inclusion criteria were included. 
The inclusion criteria were as follows: (1) either male or 
female, (2) admitted for treatment for severe P. falciparum 
malaria, (3) body weight≥40 kg, (4) age≥15 years, (5) 
on admission, pre-treatment, microscopically confirmed 
positive for asexual-stage P. falciparum parasites, (6) 
received artemisinin combination therapy (7) had no history 
of antimalarial therapy during 1 month prior admission, 
and (8) provided blood samples, before admission, for 
examination. Patients who survived had to remain in 
hospital for 4 weeks after admission. We excluded pregnant 
or lactating females, mixed malarial infection and patients 
with a history of significant systemic disease or disease 
requiring therapy, other than falciparum malaria, e.g., 
malignancy, immunosuppressive disorders, cardiovascular, 
pulmonary, gastrointestinal, neurological, endocrine, and 
metabolic diseases.
2.2. Treatments
  The patients were treated with artemisinin combination 
therapy (ACT) as part of the clinical protocol for severe P. 
falciparum malaria, e.g., artesunate 2.4 mg/kg i.v. as loading 
dose, then 1.2 mg/kg artesunate i.v. 12-hourly. Once the 
patients were able to tolerate oral therapy, they would be 
switched to oral dose of artesunate until 5 days, with the 
addition of 2 doses of oral mefloquine (25 mg/kg in divided 
doses, 8 h apart) started 12 h after the last dose of artesunate.
  Apart from specific treatment with antimalarial drugs, 
symptomatic and supportive cares were carried out to all 
patients according to standard practice of the hospital, e.g., 
mechanical ventilation for respiratory failure, hemodialysis 
for renal failure, including fever reduction by tepid sponging 
or fanning. Clinical evaluation and parasite counts were 
conducted 12-hourly until negative, and then daily. While 
the clinical laboratory tests were performed on admission 
(pre-treatment), and post-dosing, as appropriate.
2.3. Data collection
  Baseline clinical demographic and laboratory variables 
were recorded upon admission. These consisted of age, 
gender, body mass index, initial vital signs and duration of 
fever before admission, history of malaria, initial parasite 
counts, liver and spleen size, and clinical manifestations, 
e.g., chill-rigor, abdominal pain and vomiting. The 
investigating team also examined and recorded clinical 
signs, e.g., cerebral malaria (unrousable coma), severe 
anemia (pale at conjunctiva, tongue, lips and palms with 
hemoglobin<5 g/dL), respiratory distress (physically labored 
breathing), hypoglycemia (sweating and palpitation with 
blood glucose <40 mg/dL), circulatory collapse (clammy 
skin and weak peripheral pulse with systolic blood pressure 
<80 mmHg), acute renal failure (serum creatinine>3 mg/dL 
with urine output <400 mL/24 h), spontaneous bleeding 
(significant bleeding from gums, nose and gastrointestinal 
tract), multiple convulsions (≥2 convulsions observed in 24 h), 
metabolic acidosis (plasma bicarbonate<15 mmol/L or 
arterial blood pH<7.35), hemoglobinuria (dark red or black 
urine), hyperparasitemia (parasitemia ≥5%), and jaundice 
(yellow discoloration of sclera with total bilirubin>3 mg/dL). 
The clinical qualitative variables were scored as follows: 
absent=0 and present=1. Baseline hematological data, e.g., 
white-blood-cell count, red-blood-cell count, hemoglobin 
and platelet count, were determined by automated cell 
counter (Advia 120 Hematology System, Siemens Medical 
Solutions Diagnostics; commercial reagents by Roche 
Diagnostics, Berlin, Germany). The following biochemical 
parameters were measured, using a Cobas Integra 400 
(Roche Diagnostics), with commercial reagents from the 
same supplier: glucose, blood urea nitrogen, creatinine, 
total bilirubin, direct bilirubin, aminotransferases, and 
electrolytes. Thick and thin blood films were prepared from 
fingerprick blood samples and stained with Giemsa. Malaria 
parasite counts per microliter were obtained by counting the 
number of asexual parasite forms per 200 white blood cells 
on thick smears, and multiplying by the white-blood-cell 
count, or by counting the number of asexual parasite forms 
per 1 000 erythrocytes on thin smears, and multiplying by 
the red, blood-cell counts.
2.4. Outcome of treatment
  Radical cure was defined as the absence of asexual 
parasites during 28 days’ follow-up. Any antimalarial-
drug-resistant responses (RI, RII, or RIII) were categorized 
according to WHO criteria, 1973[7]. Surviving cases were the 
patients who cured and discharged well after treatment. 
Fatal cases were the patients who died in the hospital during 
treatment.
2.5. Statistical analysis
  Quantitative data were expressed as mean with standard 
deviation (SD) and qualitative data as number of observations 
with percentage(%). All reported P-values were from 
2-tailed testing, and statistical significance was set at 0.05 
probability. Descriptive statistics were used to summarize 
baseline values and demographic data. The Chi-square test 
or Fisher’s exact test was used to compare proportions, as 
appropriate, and the t-test to analyze continuous data. Risk 
verification was expressed with odds ratio (OR) and 95% 
confidence interval (95%CI). Stepwise logistic regression 
analysis was conducted to eliminate confounding factors 
and to ascertain the adjusted odds ratio, revealing fatal 
indicators in severe malaria. Validation of the logistic model 
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was illustrated by positive and negative predictive values, 
and percentage accuracy.
 
3. Results
3.1. General baseline clinical description
  Regarding the therapeutic results, patients were divided 
into 2 groups: 170 (84.1%) survived and 32 (15.9%) died. All 
surviving cases were cured and discharged well on day 28 
after initial treatment. No antimalarial-drug-resistance 
responses were found in this group. In the fatal patients, 
death occurred between 1-5 days after admission. Some 
patients, therefore, could not be completed courses of 
artesunate-mefloquine therapy. The baseline clinical 
characteristics and laboratory data for both groups are 
shown in Table 1. There were statistically significant 
differences for body mass index, initial respiratory rate, and 
serum creatinine (P<0.05). Moreover, there were statistically 
significant differences in age, initial pulse rate, white blood 
cell count, serum blood urea nitrogen, direct and total 
bilirubin, aminotransferases, potassium and bicarbonate 
(P<0.01). From the hematology profile for all patients, on 
admission most patients had reduced numbers of white 
blood cells, red blood cells, and platelets. In contrast, we 
found leucocytosis only in the fatal group. On admission, 
most of the patients in both groups had high levels of 
aminotransferases, total bilirubin, blood urea nitrogen, and 
creatinine. In addition, hypoalbuminemia, and hyponatremia 
were found in both groups.
3.2. Clinical manifestations and fatal-outcome indicators
  The patients’ clinical manifestations on admission 
are shown in Table 2. Overall,  the most common 
presentations were chill-rigor (72.2%), jaundice (68.8%) 
and hyperparasitemia (64.8%). In the fatal group, the most 
common findings were jaundice (93.7%), hyperparasitemia 
(62.5%), acute renal failure (59.3%), chill-rigor (56.2%), and 
metabolic acidosis (53.1%). To assess the importance of the 
clinical manifestations on admission, we conducted initial 
univariate analysis using the variables listed in Table 2. The 
results showed that only 7 variables-respiratory distress, 
cerebral malaria, metabolic acidosis, spontaneous bleeding, 
acute renal failure, jaundice, and circulatory collapse-were 
associated with an increased risk of death, with OR (95%CI) 
of 21.1 (6.9-64.2), 17.5 (6.0-50.7), 15.3 (6.0-38.7), 13.5 (4.3-42.3), 
9.5 (3.8-23.5), 8.4 (1.9-36.3), and 8.3 (2.0-33.8), respectively. 
No variable was considered as protective against the risk of 
death.
  Further analysis was conducted to eliminate any 
confounding factors that might affect the study results. To 
substantiate the initial results obtained, 20 statistically 
significant variables (Tables 1 and 2) were subjected to 
stepwise multiple logistic regression analysis. This yielded 
only 6 variables-jaundice, cerebral malaria, metabolic 
acidosis, body mass index, initial respiratory rate, and white 
blood cell count-as significant for the logistic model, with adjusted 
odds ratios (95%CI) of 15.2 (2.1-32.3), 4.3 (2.3-12.6), 3.3 (2.3-5.7), 
2.4 (1.9-3.5), 2.2 (1.5-2.6), and 1.7 (1.2-3.1), respectively.
Table 1
Clinical characteristics and laboratory data of study patients on admission.
Baseline data SMS(n=170) SMD(n =32)
Clinical charateristics Gender (male/female)   134/36   23/9
Age (years)*    27.5依10.5    38.0依16.3
Body mass index (kg/M2)**  20.4依3.2  25.3依3.3
Geometric mean parasite count (/毺L) 87 796  106,546 
 (320-1 154 250)  (256-1 335 320)
Duration of fever before admission (days)    4.6依2.1    4.8依1.6
Initial vital signs Auxiliary temperature (曟)  38.1依1.0  38.1依1.5
Pulse rate (/min)*    99.7依14.8   112.4依18.9
Respiratory rate (/min)**  25.8依4.9  31.8依6.7
Systolic blood (mmHg)   107.7依15.6   110.8依28.2
Diastolic blood (mmHg)    64.7依11.8    71.9依20.6
Hematology profiles White blood cell count (伊103/毺L)*     7.4依4.1    15.3依10.5
Red blood cell count (伊106/毺L)    4.4依1.0    4.1依0.9
Hemoglobin (g/dL)    14.6依11.0    14.0依13.2
Platelet count (伊103/毺L)    49.6依45.7    36.2依20.8
Biochemistry profiles Glucose(mg/dL)   130.5依45.2    133.0依103.2
Blood urea nitrogen(mg/dL)*    39.6依35.5    60.4依36.3
Creatinine (mg/dL)**    1.7依1.5    2.8依1.8
Direct bilirubin (mg/dL)*    3.8依2.9    8.2依5.8
Total bilirubin(mg/dL)*    7.5依5.8   10.9依7.4
Albumin(g/dL)    3.3依0.7    3.1依0.6
Aspartate aminotransferase (U/L)*    106.3依101.7    466.7依442.9
Alanine aminotransferase (U/L)*    69.1依61.5    212.9依181.5
Sodium(mmol/L) 132.0依4.8 133.0依8.0
Potassium(mmol/L)*    3.8依0.6     5.4依6.2
Bicarbonate(mmol/L)*  20.1依3.9   15.5依8.6
*: P<0.01, **: P<0.05, SMS: severe P. falciparum malaria survival patients; SMD: severe P. falciparum malaria dead patients.
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3.3. Validation study
  In the validation study logistic model, the positive 
predictive value was 92.9%, and the negative predictive 
value was 89.9%, with 90.0% accuracy.
4. Discussion
  Although P. falciparum malaria is the major cause of 
death among malaria patients, particularly in tropical 
and subtropical regions, deaths may be reduced by early 
diagnosis of malaria and prompt effective treatment[8,9]. 
Thus, it is crucial to predict the most likely course of disease 
as accurately as possible, particularly for in-hospital 
patient management. Various study teams in different 
regions have studied the fatal indicators of severe malaria; 
however, few studies have been conducted in Southeast 
Asia. In the past decade, most reports have established the 
indicators of fatal outcomes in pediatric severe-malaria 
cases, focusing on endemic areas, such as Africa. This 
study described the clinical features of adult patients with 
severe P. falciparum malaria in the Intensive Care Unit of 
the Hospital for Tropical Diseases (HTD) and the clinical 
indicators associated with a lethal outcome. In a previous 
report, we noted the mortality rate among malaria patients 
admitted to the HTD was 1.8%[10]. The HTD was a tertiary-
care setting for tropical diseases, particularly for the 
management of severe malaria; therefore, it is unsurprising 
that the malaria mortality rate was low compared with other 
recent reports[5,11,12]. In this study, however, we enrolled 
patients according to the randomization process along 
with the inclusion and exclusion criteria. As a result, the 
flaw of this study was the lack of epidemiological data for 
comparison with the previous report. However, the start-
point was adult patients with complicated P. falciparum 
malaria. These patients were enrolled into the study after 
admission, without any selection bias, by clinicians. We 
were, therefore, confident that our results had described the 
complete spectrum of fatal indicators in this setting.
  The pathophysiological processes causing severe malaria 
are complex and currently incompletely understood. 
Classification of disease severity, in malaria, is still crucial 
to the provision of effective care, particularly for in-hospital 
patient management. Various reports have shown the 
factors associated with treatment outcomes among malaria 
patients. Recently, metabolic acidosis and cerebral malaria 
have been reported as simple predictors of therapeutic 
outcome in adult patients with severe malaria[9]. There were 
some consistencies with another report, which showed that 
cerebral malaria, acute renal failure, needing ventilator 
support, and severe anemia, were indicators of mortality 
for adult malaria patients[13]. Robinson and coworker 
emphasized that unconsciousness, renal failure, and 
pulmonary edema, were significant predictors of mortality 
among adult patients with severe malaria[5]. The results of 
our study showed some agreement with these other studies; 
we have shown that cerebral malaria, metabolic acidosis, and 
initial respiratory rate, in adult patients with complicated 
P. falciparum malaria, were associated with fatal outcome. 
However, acute renal failure, severe anemia, and respiratory 
distress including need for ventilator support and pulmonary 
edema were not included in our study model. Regarding 
our study conditions, the hospital’s facilities and treatment 
procedures probably contributed to the differences in results 
from these former studies. All severe malaria patients 
admitted to the HTD were monitored closely by medical staff, 
the blood bank unit was well-managed, and all life-support 
equipment (ventilator, hemodialyzer) was kept on stand-by 
as a matter of routine. For most patients, therefore, disease 
severity was detected before complications developed.
  Recently, subcutaneous fatty tissue and overweight have 
also been established as factors associated with disease 
severity in malaria[8,14]; this may be why body mass index 
(BMI) was one clinical indicator associated with a fatal 
outcome among the malaria patients in our own study. 
Hematological changes during malaria infection have been 
well-described[15-17]. White-blood-cell counts might be 
high, normal, or low, in malaria infection. Three previous 
reports have confirmed the frequent presence of low white-
Table 2
Clinical manifestations of study patients and number of deaths.
Clinical manifestation Total number of diagnostic patients (cases) Number in fatal group (cases) Odds ratio(95% CI)
Past history of malaria in last 1 year   45   3 0.5 (0.1-1.9)
Chill-rigors 146 18   2.9 (0.6-13.3)
Abdominal pain   57   3 0.9 (0.2-3.9)
Vomiting   95   3 0.3 (0.1-1.4)
Hepatomegaly   87   9 1.1 (0.4-2.7)
Splenomegaly   22   3 15 (0.4-5.6)
Cerebral malaria*  34 14 17.5 (6.0-50.7)
Severe anemia  17   5   4.4 (1.4-14.1)
Respiratory distress*  38 15 21.1 (6.9-64.2)
Hypoglycemia   9   3   4.8 (1.1-21.0)
Circulatory collapse*   9   4   8.3 (2.0-33.8)
Acute renal failure*  53 19   9.5 (3.8-23.5)
Spontaneous bleeding*  16   8 13.5 (4.3-42.3)
Multiple convulsion   8   2   3.0 (0.6-16.2)
Metabolic acidosis*  34 17 15.3 (6.0-38.7)
Hemoglobinuria  95 11 1.2 (0.5-3.2)
Hyperparasitemia 131 20 0.9 (0.4-1.9)
Jaundice* 139 30   8.4 (1.9-36.3)
*: P<0.01
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blood-cell counts in acute malaria[18-20]. In contrast, an 
African study of child malaria patients commonly found 
high white-blood-cell counts; however, this factor was not 
necessarily indicative of a poor prognosis[21]. Regarding 
our results, it was not surprising that white-blood-cell 
count was one of the fatal indicators. Since controversy 
still remains over this factor, more investigations should 
be undertaken, to distinguish on viral or bacterial co-
infections, other inflammations or traumas and stress during 
malaria treatment. In severe P. falciparum malaria, jaundice 
was a common feature, attributed in part to liver damage 
and the hemolysis of both parasitized and non-parasitized 
erythrocytes[22]. In our study, jaundice was included as 
a predictor of mortality; this illustrated a inconsistency 
with another report which showed that jaundice was not 
associated with therapeutic outcome in severe malaria[13]. 
Regarding the results of this study, jaundice (total 
bilirubin>3 mg/dL) was seen in most patients. In this study, 
the direct parameters for hemolysis were not measured, 
but a decrease in red-cell mass, e.g., hemoglobin, (without 
bleeding), concomitant with an increase in unconjugated 
bilirubinemia after admission, might explain the hemolytic 
jaundice.
  Regarding validation of the study results, we found that the 
validity indices were slightly low. This might be due to the 
small sample size in the study, as we had a limited time to 
recruit patients.
  In conclusion, a presentation of multiple complications 
in severe P. falciparum malaria patients after admission 
made clinical management difficult. Even in tertiary 
hospitals, clinical management difficulties may arise due 
to the deterioration of patient status at any time during 
hospitalization. In this situation, our results indicated that 
fatal indicators in severe malaria might differ in different 
settings. We recommended that further studies on fatal 
indicators in severe malaria should compare data from 
different geographical areas, to elicit evidence-based field 
data on potentially fatal indicators in different settings.
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